New Promises and Challenges on Inflammation and Atherosclerosis: Insights From CANTOS and CIRT Trials.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Targeting endothelial vascular cell adhesion molecule-1 in atherosclerosis: drug discovery and development of vascular cell adhesion molecule-1-directed novel therapeutics.Cardiovascular research · 2023
   Review
2. Inflammation Beats Cholesterol: A Comment on the Unequivocal Driver of Cardiovascular Disease Risk.Journal of clinical medicine · 2023
   Article
3. Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc).Frontiers in pharmacology · 2022
   Article
4. Immunobiology of Atherosclerosis: A Complex Net of Interactions.International journal of molecular sciences · 2019
   Review
5. Factors Associated With Myocardial Infarction Reoccurrence.The Journal of cardiovascular nursing
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as